By Angela Betsaida B. Laguipo, BSN Jan 2 2020
The BCG (Bacillus Calmette–Guérin) vaccine is given intradermally and has variable efficacy against pulmonary tuberculosis, a highly contagious disease that is responsible for about 1.5 million deaths in 2018 across the globe. Now, a team of scientists has found a new route for the vaccine to be administered – injecting it directly into the blood (intravenous).
The study, which was recently published in the journal Nature, revealed that delivering the vaccine directly into the bloodstream, rather than intradermally or under the skin, led to near-total protection in a group of macaques.
The team of scientists from the U.S. National Institute of Allergy and Infectious Diseases and the University of Pittsburgh School found that delivering a high dose of the vaccine intravenously greatly improves the drug’s ability to protect against the deadly disease. Image Credit: Kateryna Kon / Shutterstock.com "The effects were amazing"
The researchers administered the vaccine under the skin, through an aerosol, or intravenously, in groups of monkeys. They evaluated the immune response of the animals after 24 weeks and found that the most effective responders were those who received the intravenous vaccine.
Six months after administering the vaccine, the team exposed the monkeys to a virulent and potent strain of Mycobacterium tuberculosis, the causative agent of pulmonary tuberculosis (PTB). The findings of the study show that nine out of 10 monkeys who received the intravenous vaccine were highly protected, while six out of 10 monkeys showed no infection at all.
Further, three of the monkeys had only very low counts of the bacteria in the lung tissue. Meanwhile, all unvaccinated monkeys and those who received the vaccine through the skin or aerosol showed signs of greater infection.
The vaccine prevented tuberculosis in 90 percent of the monkeys. One of the most interesting results shows that six out of 10 monkeys injected with the vaccine intravenously never developed an initial infection when they were exposed to Mycobacterium tuberculosis.
The effects are amazing. When we compared the lungs of animals given the vaccine intravenously versus the standard route, we saw a 100,000-fold reduction in bacterial burden. Nine out of 10 animals showed no inflammation in their lungs.” Dr. JoAnne Flynn, Professor of Microbiology & Molecular Genetics, The Pitt Center for Vaccine Research What is the BCG vaccine? Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology